Navigation Links
Pharma IQ's Solubility Report
Date:4/27/2012

LONDON, April 27, 2012 /PRNewswire/ --

Pharma IQ has just published the results of an industry-wide Solubility Report, conducted recently among 3,000 pharmaceutical solubility specialists.

The results showed that improving API solubility is the greatest challenge for nearly 60% of respondents, followed by exploring novel drug delivery routes (specified by 26% of respondents). The rest of the survey participants indicated improving API stability and formulation of biopharmaceuticals as the major issues.

In terms of improving compound solubility, the most popular compound modification strategies used by respondents were developing an amorphous form and adding an excipient. The least popular ones were changing the crystal structure and addition of a salt.

The report was created as a part of the pre-conference research for Improving Solubility Forum, taking place 26-28 June, 2012 in Munich.

The results helped to shape the agenda and final speaker line-up, which features David Elder, Externalisation Director from GlaxoSmithKline who will present his thoughts on model guided formulation development and Lennart Lindfords, Pharmaceutical and Analytical R&D from AstraZeneca, who will be leading a session on Computer Calculations of Poorly Soluble Drug Transport Across the Gastrointestinal Cell Wall.

Other important topics expressed by survey respondents and that will be discussed at the event include:

  • The Impact of Solubility During Pharmaceutical Research and Development (Christoph Saal, Senior Manager Molecule Characterisation, Merck)
  • The impact of surfactants on dissolution, in-vitro permeability and bioavailability of poorly soluble drugs (Menno Vliestra, Global Supply Chain, Finance and HR, Roche)
  • The use the knowledge and experience of other industries to help aid solubility improvement in pharmaceuticals with new updates from Zhijun Liu
    Professor, Medicinal Plant Lab, School of Renewable Natural Resources
    Louisiana State University Agricultural Centre

To access more reports or to find out more about Pharmaceutical Distribution 2011 please visit http://www.improvingsolubility.com/NEWS, email enquire@iqpc.co.uk or call +44(0)207-368-1300.

Media contact: Joanna Checinska, +44(0)20-7368-9421, joanna.checinska@iqpc.co.uk - Please contact for more information or images.

Press are invited to attend this important industry forum, if you would like a complimentary press pass please email Joanna Checinska (joanna.checinska@iqpc.co.uk)


'/>"/>
SOURCE Pharma IQ
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
Breaking Medicine Technology:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... TopConsumerReviews.com recently ... of Eyeglasses . , Millions of individuals in the United States and Canada ... become a way to both correct vision and make a fashion statement. Even celebrities ...
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
Breaking Medicine News(10 mins):